Chief Executive Officer
Mr. Duncan has more than 20 years of healthcare and life sciences experience including senior commercial, strategy and general management roles at GlaxoSmithKline, IVAX Pharmaceuticals, and Healthcare at Home. Prior to accepting the interim Chief Executive Officer role at Concordia International Corp., Mr. Duncan previously served as President of Concordia’s International segment since January 2016. Prior to his role as President, he was Managing Director for Concordia’s International segment.
Chief Financial Officer
Mr. Ahmad brings over 20 years of experience in the pharmaceutical, distribution, telecommunications and accounting industries. Prior to becoming the Chief Financial Officer of Concordia International Corp, Mr. Ahmad was CFO of the Company’s International segment, and before that, Vice President, Finance and Controller of the Company. Prior to joining the Company in 2013, Mr. Ahmad was the Chief Financial Officer of the Indian operations of Ingram Micro Mobility (formerly BrightPoint), based in New Delhi, India, from February 2012 to May 2013. Prior to his role at BrightPoint, Mr. Ahmad held several finance roles of increasing responsibility with Nortel Networks from 2003 to 2012, based in Brampton, Ontario, Canada; Seoul, South Korea; and Beijing, China. Mr. Ahmad started his career in an audit function with Deloitte LLP in Toronto. Mr. Ahmad holds a B. Comm from the University of Toronto and an MBA from the Ivey School of Business, University of Western Ontario.
Chief Operations Officer
Mr. Belk has more than 30 years of experience in manufacturing, packaging, supply chain and distribution, and 20 years in senior management and leadership positions including his role as Operations Director for Teva. As Chief Operations Officer for Concordia, Mr. Belk leads all operations functions globally, including scientific affairs (medical, regulatory and quality), supply (supply chain and supplier alliance management), new product introductions and technical operations.
Chief Corporate Development Officer
Mr. Clark brings to Concordia more than 25 years of experience in the pharmaceutical industry, including previous senior roles at Glenmark Pharmaceuticals and IVAX Pharmaceuticals. Most recently, Mr. Clark served as Chief Strategy Officer at AMCo Pharmaceuticals from 2013 to 2015. As Chief Corporate Development Officer for Concordia International Corp., Mr. Clark will focus on leading the Company’s corporate development initiatives including M&A, strategy formulation & implementation and expanding its pipeline of medicines.
President of Concordia North America
Mr. Pai has more than 25 years of experience in the healthcare industry including working across the value chains of medical device, pharma, pharmaceutical distribution and specialty pharma distribution companies. He spent the first part of his career working in operational and technical roles to manage the development, manufacture and launch of generic pharmaceutical products for companies including Abbott Laboratories, Wyeth and Actavis. Mr. Pai subsequently transitioned to a more commercial focus through a business development role in which he spent extensive time in Asia to seek portfolio opportunities for Alpharma’s U.S. market segment. Most recently, he held various general management roles leading pharmaceutical distribution and specialty pharma businesses for Cardinal Health.
Chief Legal Officer and Secretary
Mr. Tallarico is Chief Legal Officer and Secretary of Concordia International Corp. Mr. Tallarico manages the Global legal function of the Corporation. Prior to joining the Corporation in 2014, Mr. Tallarico practiced law at Fasken Martineau DuMoulin LLP, an international law firm based out of Toronto, Ontario, with a particular focus on corporate governance, corporate finance and M&A transactions. During his time with the Corporation, Mr. Tallarico has been actively involved and instrumental in various M&A transactions valued at over $4.5 billion. Mr. Tallarico holds a B.A. from the University of Toronto and a J.D. from the University of Windsor.